Skip to main content

Qiagen Value Stock - Dividend - Research Selection


ISIN: NL0012169213, WKN: A2DKCH

Market price date: 16.05.2022
Market price: 46,35 USD

Qiagen Fundamental data and company key figures of the share

Annual reports in USD
Key figures 15-02-2022
Cash flow
Net operating cash flow 639.001.000
Capital Expenditures -189.904.000
Free cash flow 449.096.992
Balance sheet
Total Equity 3.096.550.000
Liabilities & Shareholders equity 6.146.950.000
Income statement
Net income 512.599.000
Eps (diluted) 2,210
Diluted shares outstanding 227.074.000
Net sales/revenue 2.251.660.000

Fundamental ratios calculated on: 16-05-2022

Key figures 16-05-2022
Cash flow
P/C 16,47
P/FC 23,44
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization10.524.879.872,00 USD
IndicesDax,HDAX,MSCI World Index,STOXX EUROPE 600,TecDAX
SectorsLife Sciences Tools & Services
Raw Data SourceUS GAAP in Millionen USD
Stock Split2017-01-26,962.0000/1000.0000; 2017-01-25,962.0000/1000.0000; 2000-07-14,4.0000/1.0000; 1999-07-16,2.0000/1.0000

Description of the company

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer

The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

QIAGEN NV : Berenberg keeps its Buy rating

Berenberg analyst Odysseas Manesiotis maintains his Buy rating on the stock. The target price remains unchanged at EUR 50. | May 16, 2022

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

HILDEN, Germany & GERMANTOWN, Md., May 16, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat-Dx Rise – a high-capacity version of the QIAstat-Dx automated syndromic system – and enhancements to the menu of tests for the fully integrated one-step molecular testing solution that provides results in about one hour.

What Type Of Shareholders Own The Most Number of Qiagen N.V. (NYSE:QGEN) Shares?

If you want to know who really controls Qiagen N.V. ( NYSE:QGEN ), then you'll have to look at the makeup of its share...

QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.

HILDEN, Germany & GERMANTOWN, Md., May 11, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has signed agreements to acquire a 96% majority ownership stake in BLIRT SA (Polish Stock Exchange: BLR), a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland.

Qiagen to acquire 96% majority stake in BLIRT SA, terms not disclosed

QIAGEN announced that it ... QGEN

QIAGEN Proposes Expansion of Supervisory Board

VENLO, the Netherlands, May 11, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has extensive experience from start-ups to corporate companies, as a new member of the Supervisory Board.

Cable companies to offer effectively free internet to low-income homes

The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.

Qiagen receives CE-IVD certification for NeuMoDx HSV 1/2 Quant Assay

Qiagen announced that its... QGEN